T0	Participants 25 67	men with locally advanced prostate cancer:
T1	Participants 390 486	men treated with RT and androgen deprivation therapy (ADT) for locally advanced prostate cancer.
T2	Participants 495 618	Between 1987 and 1992, 945 eligible men with locally advanced prostate cancer were enrolled in a phase 3 trial (RTOG 85-31)
T3	Participants 763 786	for 788 (83%) subjects.
T4	Participants 1632 1674	men with locally advanced prostate cancer.